Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTranscode Therapeutics schedules 2026 annual meeting for July 2, sets proposal deadline
Filed June 1, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
low
Annual stockholder meeting scheduled for July 2, 2026, with record date of May 28, 2026 for voting eligibility. Meeting date is more than 30 days earlier than the 2025 meeting held on August 29.
Item 8.01 view on EDGAR → -
low
Stockholders must submit proposals for proxy inclusion by June 11, 2026 at 5:00 p.m. ET. The accelerated deadline is ten days from this announcement due to the earlier meeting date.
Item 8.01 view on EDGAR →
Summary
Transcode Therapeutics filed a routine procedural disclosure announcing its 2026 annual stockholder meeting will be held on July 2, 2026, an undisclosed amount one month earlier than last year's August 29 meeting. The company set May 28, 2026 as the record date for determining which stockholders are eligible to vote. The earlier meeting date triggered an accelerated deadline for stockholder proposals.
Any stockholder wishing to include a proposal in the company's proxy materials must submit it by June 11, 2026 at 5:00 p.m. Eastern Time—just ten days after this announcement. This is a standard procedural requirement when annual meeting dates shift significantly. For retail investors, this is purely administrative. Unless you plan to submit a stockholder proposal, no action is needed. Watch for the actual proxy materials closer to July, which will detail board nominees and any matters requiring your vote.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify